Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Etalocib (LY293111) is a novel diaryl ether carboxylic acid derivative, is a selective and potent inhibitor of the lipoxygenase pathway either via antagonism of the leukotriene B4 (LTB4) receptor or directly through 5'-lipoxygenase. It has antineoplastic activities.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 139.00 | |
5 mg | In stock | $ 347.00 | |
10 mg | In stock | $ 563.00 | |
25 mg | In stock | $ 890.00 | |
50 mg | In stock | $ 1,230.00 | |
100 mg | In stock | $ 1,670.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 447.00 |
Description | Etalocib (LY293111) is a novel diaryl ether carboxylic acid derivative, is a selective and potent inhibitor of the lipoxygenase pathway either via antagonism of the leukotriene B4 (LTB4) receptor or directly through 5'-lipoxygenase. It has antineoplastic activities. |
Synonyms | LY293111, VML295 |
Molecular Weight | 544.6 |
Formula | C33H33FO6 |
CAS No. | 161172-51-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (183.62 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Etalocib 161172-51-6 Apoptosis GPCR/G Protein Immunology/Inflammation Leukotriene Receptor LTR antiinflammatory VML 295 inhibit VML-295 LY-293111 LY293111 Pulmonary LY 293111 Inhibitor VML295 asthma bronchiectasis inhibitor